Matches in SemOpenAlex for { <https://semopenalex.org/work/W2391464005> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2391464005 endingPage "3" @default.
- W2391464005 startingPage "3" @default.
- W2391464005 abstract "3 Background: Tumors use the PD-1 pathway to evade immune surveillance. Pembrolizumab, an anti-PD-1 monoclonal antibody, has shown antitumor activity in advanced cancers. We assessed the safety and efficacy of pembrolizumab in patients with advanced gastric cancer in KEYNOTE-012 (Clinicaltrials.gov identifier NCT01848834). Methods: Archival tumor samples from patients from Asia-Pacific (AP) and rest of the world (ROW) with recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction were screened for PD-L1 expression using a prototype IHC assay with the 22C3 antibody. Only patients with distinctive stromal or ≥1% tumor nest cell PD-L1 staining were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks for up to 24 months or until complete response, progression, or unacceptable toxicity. Imaging was performed every 8 weeks. Primary efficacy end point is ORR assessed per RECIST v1.1 by independent central review. Secondary end points include duration of response, PFS, and OS. Results: Of the 162 patientts screened, 65 (40%) were PD-L1 + . Of these 65 patients, 39 enrolled (19 from AP, 20 from ROW; median age, 63 years [range 33-78]). The number of prior therapies for advanced disease ranged from 0 to 5; 67% received ≥2 prior therapies. Median follow-up duration was 8.8 months (range 6.2-12.6); 13 patients (33%) remain on therapy. Four patients experienced 5 total grade 3-5 drug-related adverse events: peripheral sensory neuropathy, fatigue, decreased appetite, hypoxia, and pneumonitis (n = 1 each). There was 1 drug-related death (hypoxia). ORR was 22% (95% CI 10-39) by central review and 33% (95% CI 19-50) by investigator review. Median time to response was 8 weeks (range 7-16), with a median response duration of 24 weeks (range 8+ to 33+). PD-L1 expression level was associated with ORR (1-sided P = 0.10). The 6-month PFS rate was 24%. The 6-month OS rate was 69%. Conclusions: Pembrolizumab demonstrated manageable toxicity and promising antitumor activity in advanced gastric cancer. These results support the ongoing development of pembrolizumab for gastric cancer. Clinical trial information: NCT01848834." @default.
- W2391464005 created "2016-06-24" @default.
- W2391464005 creator A5017229890 @default.
- W2391464005 creator A5019508460 @default.
- W2391464005 creator A5045982804 @default.
- W2391464005 creator A5050481393 @default.
- W2391464005 creator A5050684671 @default.
- W2391464005 creator A5051154520 @default.
- W2391464005 creator A5058894394 @default.
- W2391464005 creator A5061867713 @default.
- W2391464005 creator A5062199973 @default.
- W2391464005 creator A5062557677 @default.
- W2391464005 creator A5073330859 @default.
- W2391464005 creator A5074882255 @default.
- W2391464005 creator A5075923858 @default.
- W2391464005 creator A5084659842 @default.
- W2391464005 creator A5088734038 @default.
- W2391464005 creator A5089998052 @default.
- W2391464005 creator A5090832721 @default.
- W2391464005 date "2015-01-20" @default.
- W2391464005 modified "2023-10-05" @default.
- W2391464005 title "Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012." @default.
- W2391464005 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.3" @default.
- W2391464005 hasPublicationYear "2015" @default.
- W2391464005 type Work @default.
- W2391464005 sameAs 2391464005 @default.
- W2391464005 citedByCount "57" @default.
- W2391464005 countsByYear W23914640052015 @default.
- W2391464005 countsByYear W23914640052016 @default.
- W2391464005 countsByYear W23914640052017 @default.
- W2391464005 countsByYear W23914640052018 @default.
- W2391464005 countsByYear W23914640052019 @default.
- W2391464005 countsByYear W23914640052020 @default.
- W2391464005 countsByYear W23914640052021 @default.
- W2391464005 countsByYear W23914640052022 @default.
- W2391464005 crossrefType "journal-article" @default.
- W2391464005 hasAuthorship W2391464005A5017229890 @default.
- W2391464005 hasAuthorship W2391464005A5019508460 @default.
- W2391464005 hasAuthorship W2391464005A5045982804 @default.
- W2391464005 hasAuthorship W2391464005A5050481393 @default.
- W2391464005 hasAuthorship W2391464005A5050684671 @default.
- W2391464005 hasAuthorship W2391464005A5051154520 @default.
- W2391464005 hasAuthorship W2391464005A5058894394 @default.
- W2391464005 hasAuthorship W2391464005A5061867713 @default.
- W2391464005 hasAuthorship W2391464005A5062199973 @default.
- W2391464005 hasAuthorship W2391464005A5062557677 @default.
- W2391464005 hasAuthorship W2391464005A5073330859 @default.
- W2391464005 hasAuthorship W2391464005A5074882255 @default.
- W2391464005 hasAuthorship W2391464005A5075923858 @default.
- W2391464005 hasAuthorship W2391464005A5084659842 @default.
- W2391464005 hasAuthorship W2391464005A5088734038 @default.
- W2391464005 hasAuthorship W2391464005A5089998052 @default.
- W2391464005 hasAuthorship W2391464005A5090832721 @default.
- W2391464005 hasConcept C121608353 @default.
- W2391464005 hasConcept C126322002 @default.
- W2391464005 hasConcept C141071460 @default.
- W2391464005 hasConcept C143998085 @default.
- W2391464005 hasConcept C197934379 @default.
- W2391464005 hasConcept C2777701055 @default.
- W2391464005 hasConcept C2777714996 @default.
- W2391464005 hasConcept C2779524853 @default.
- W2391464005 hasConcept C2780057760 @default.
- W2391464005 hasConcept C71924100 @default.
- W2391464005 hasConcept C90924648 @default.
- W2391464005 hasConceptScore W2391464005C121608353 @default.
- W2391464005 hasConceptScore W2391464005C126322002 @default.
- W2391464005 hasConceptScore W2391464005C141071460 @default.
- W2391464005 hasConceptScore W2391464005C143998085 @default.
- W2391464005 hasConceptScore W2391464005C197934379 @default.
- W2391464005 hasConceptScore W2391464005C2777701055 @default.
- W2391464005 hasConceptScore W2391464005C2777714996 @default.
- W2391464005 hasConceptScore W2391464005C2779524853 @default.
- W2391464005 hasConceptScore W2391464005C2780057760 @default.
- W2391464005 hasConceptScore W2391464005C71924100 @default.
- W2391464005 hasConceptScore W2391464005C90924648 @default.
- W2391464005 hasIssue "3_suppl" @default.
- W2391464005 hasLocation W23914640051 @default.
- W2391464005 hasOpenAccess W2391464005 @default.
- W2391464005 hasPrimaryLocation W23914640051 @default.
- W2391464005 hasRelatedWork W2047967234 @default.
- W2391464005 hasRelatedWork W2806838035 @default.
- W2391464005 hasRelatedWork W2982229394 @default.
- W2391464005 hasRelatedWork W3003430946 @default.
- W2391464005 hasRelatedWork W3005570342 @default.
- W2391464005 hasRelatedWork W3135441417 @default.
- W2391464005 hasRelatedWork W3136244698 @default.
- W2391464005 hasRelatedWork W4308571590 @default.
- W2391464005 hasRelatedWork W4323544648 @default.
- W2391464005 hasRelatedWork W4386083912 @default.
- W2391464005 hasVolume "33" @default.
- W2391464005 isParatext "false" @default.
- W2391464005 isRetracted "false" @default.
- W2391464005 magId "2391464005" @default.
- W2391464005 workType "article" @default.